Nyamache Anthony Kebira, Muigai Anne W T, Ng'ang'a Zipporah, Khamadi Samoel A
Department of Plant and Microbial Sciences, Kenyatta University, Nairobi, Kenya.
AIDS Res Hum Retroviruses. 2013 Aug;29(8):1105-9. doi: 10.1089/aid.2012.0284. Epub 2013 May 21.
A switch of HIV coreceptor usage from CCR5 to CXCR4 occurs in AIDS pathogenesis and may play a critical role in the use of entry inhibitors. To determine the potential usefulness of maraviroc and other CCR5 antagonists among drug-naive and experienced patients in Kenya, the env-C2-V3 gene was successfully sequenced in samples from 176 (98 men and 78 female) consenting subjects between January 2009 and December 2012. In silico CPSSM, webPSSM/, and (ds) Kernel tools were used in predicting coreceptor usage. On the basis of the env V3 loop sequences, 84.1% (148) were reported with R-5 tropism, 4.5% (5) were dual tropic, while 13.4% (23) were of X4 tropism. However, similar to previous studies conducted in Kenya on genetic diversity, HIV-1 subtype A1 (73.9%; 130/176) still remains the most dominant subtype. The high levels of R5 tropism among the studied Kenyan infected populations suggested the potential use of CCR5 antagonists as new therapeutic options in Kenya.
在艾滋病发病机制中，HIV共受体使用情况会从CCR5转换为CXCR4，这可能在进入抑制剂的使用中起关键作用。为了确定马拉维若及其他CCR5拮抗剂在肯尼亚未接受过治疗和接受过治疗的患者中的潜在效用，2009年1月至2012年12月期间，成功对176名（98名男性和78名女性）同意参与研究的受试者的样本进行了env-C2-V3基因测序。利用计算机CPSSM、webPSSM/和（ds）内核工具预测共受体使用情况。根据env V3环序列报告，84.1%（148例）为R-5嗜性，4.5%（5例）为双嗜性，而13.4%（23例）为X4嗜性。然而，与此前在肯尼亚进行的关于基因多样性的研究相似，HIV-1 A1亚型（73.9%；130/176）仍然是最主要的亚型。在肯尼亚受研究的感染人群中，R5嗜性水平较高，这表明CCR5拮抗剂有可能作为新的治疗选择在肯尼亚使用。
